Primary Immunodeficiency Disease
10
0
1
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
80%
8 trials in Phase 3/4
100%
4 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10)
An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease
Efficacy, Safety, and Pharmacokinetics of Shu Yang IVIG
Efficacy and Safety and Pharmacokinetics of Boya IVIG
Study to Investigate Efficacy, Safety and Pharmacokinetics of BT595 in Subjects With PID
Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
Pediatric Primary Immunodeficiency Disease (PID) in China
High Infusion Rate Study of Immunoglobulin Intravenous (Human) 10% (NewGam)
Clinical and Laboratory Online Patient- and Research Database for Primary Immunodeficiencies in Switzerland